{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T00:21:52Z","timestamp":1794183712831,"version":"4.8.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007075","name":"ESMO","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.esmoop.2025.105125","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T14:37:30Z","timestamp":1749479850000},"page":"105125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pan-Asia adapted ESMO Clinical Practice Guideline for the management of patients with newly diagnosed and relapsed epithelial ovarian cancer"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8377-5692","authenticated-orcid":false,"given":"S.","family":"Nag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2472-8306","authenticated-orcid":false,"given":"I.","family":"Ray Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6742-6378","authenticated-orcid":false,"given":"S.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3266-3322","authenticated-orcid":false,"given":"N.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Mulya Sari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0833-3489","authenticated-orcid":false,"given":"K.","family":"Harano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.M.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.F.","family":"Ang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.V.","family":"Que","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3482-0176","authenticated-orcid":false,"given":"W.Y.","family":"Chay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.-C.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Ativitavas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Tangjitgamol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9977-9645","authenticated-orcid":false,"given":"C.-H.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.Y.M.","family":"Heong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Contreras Tolentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.","family":"Ngu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5897-8309","authenticated-orcid":false,"given":"J.","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7354-6977","authenticated-orcid":false,"given":"M.","family":"Yunokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.L.H.","family":"Hanafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Smyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3006-8375","authenticated-orcid":false,"given":"J.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Pentheroudakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7655-1608","authenticated-orcid":false,"given":"A.","family":"Maheshwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cervantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0826-5818","authenticated-orcid":false,"given":"M.","family":"Basade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3592-7194","authenticated-orcid":false,"given":"A.","family":"Oaknin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2025.105125_bib1","series-title":"Global cancer observatory: cancer today","author":"Ferlay","year":"2024"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105125_bib2","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105125_bib3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1086\/321805","article-title":"Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients","volume":"33","author":"Dykewicz","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105125_bib4","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1093\/annonc\/mdx310","article-title":"ESMO-magnitude of clinical benefit scale version 1.1","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105125_bib5","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol"},{"issue":"68","key":"10.1016\/j.esmoop.2025.105125_bib6","doi-asserted-by":"crossref","first-page":"112258","DOI":"10.18632\/oncotarget.22733","article-title":"Prevalence of pathogenic germline variants detected by multigene sequencing in unselected Japanese patients with ovarian cancer","volume":"8","author":"Hirasawa","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105125_bib7","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1097\/IGC.0000000000001065","article-title":"The first nationwide multicenter prevalence study of germline BRCA1 and BRCA2 mutations in Chinese ovarian cancer patients","volume":"27","author":"Wu","year":"2017","journal-title":"Int J Gynecol Cancer"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105125_bib8","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.1111\/cas.15166","article-title":"Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer","volume":"112","author":"Paik","year":"2021","journal-title":"Cancer Sci"},{"key":"10.1016\/j.esmoop.2025.105125_bib9","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1200\/GO.21.00051","article-title":"Prevalence of BRCA1 and BRCA2 mutations among patients with ovarian, primary peritoneal, and fallopian tube cancer in India: a multicenter cross-sectional study","volume":"7","author":"Gupta","year":"2021","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.esmoop.2025.105125_bib10","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.gore.2019.07.007","article-title":"BRCA mutation in high grade epithelial ovarian cancers","volume":"29","author":"Manchana","year":"2019","journal-title":"Gynecol Oncol Rep"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105125_bib11","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.31557\/APJCP.2020.21.8.2381","article-title":"Prevalence of tissue BRCA gene mutation in ovarian, fallopian tube, and primary peritoneal cancers: a multi-institutional study","volume":"21","author":"Lertkhachonsuk","year":"2020","journal-title":"Asian Pac J Cancer Prev"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105125_bib12","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ygyno.2006.06.013","article-title":"Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study","volume":"102","author":"Bell","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105125_bib13","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/IGC.0b013e31823fd413","article-title":"Adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: an analysis of fully staged patients","volume":"22","author":"Takada","year":"2012","journal-title":"Int J Gynecol Cancer"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105125_bib14","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.annonc.2020.08.2102","article-title":"ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer","volume":"31","author":"Miller","year":"2020","journal-title":"Ann Oncol"},{"issue":"27","key":"10.1016\/j.esmoop.2025.105125_bib15","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1200\/JCO.2010.33.8566","article-title":"Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial","volume":"29","author":"Pignata","year":"2011","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105125_bib16","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1158\/1078-0432.CCR-20-3546","article-title":"An Open-label, multicenter, single-arm, phase II study of fluzoparib in patients with germline BRCA1\/2 mutation and platinum-sensitive recurrent ovarian cancer","volume":"27","author":"Li","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.esmoop.2025.105125_bib17","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.21.01511","article-title":"Fuzuloparib maintenance therapy in patients with platinum-sensitive, recurrent ovarian carcinoma (FZOCUS-2): a multicenter, randomized, double-blind, placebo-controlled, phase III trial","volume":"40","author":"Li","year":"2022","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105125_bib18","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","article-title":"Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial","volume":"34","author":"Ray-Coquard","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2025.105125_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.04.024","article-title":"Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA\/ENGOT-OV26\/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer","volume":"189","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Eur J Cancer"},{"issue":"34","key":"10.1016\/j.esmoop.2025.105125_bib20","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1200\/JCO.22.01003","article-title":"A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO\/GOG-3020\/ENGOT-ov45)","volume":"40","author":"Monk","year":"2022","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105125_bib21","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.annonc.2024.08.2241","article-title":"Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial","volume":"35","author":"Monk","year":"2024","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105125_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100558","article-title":"Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: individual patient data and trial-level meta-analysis","volume":"7","author":"Gulia","year":"2022","journal-title":"ESMO Open"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105125_bib23","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2016.71.0632","article-title":"Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum","volume":"35","author":"Gershenson","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105125_bib24","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/annonc\/mdq352","article-title":"Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial","volume":"22","author":"Poveda","year":"2011","journal-title":"Ann Oncol"},{"issue":"10324","key":"10.1016\/j.esmoop.2025.105125_bib25","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(21)02175-9","article-title":"Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281\/LOGS): an international, randomised, open-label, multicentre, phase 2\/3 trial","volume":"399","author":"Gershenson","year":"2022","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.esmoop.2025.105125_bib26","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105125_bib27","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/jnci\/djs494","article-title":"Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2","volume":"105","author":"McLaughlin","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.esmoop.2025.105125_bib28","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1016\/j.ygyno.2024.07.110","article-title":"Fuzuloparib as maintenance therapy among patients with advanced ovarian cancer after a response to first-line platinum-based chemotherapy: results from a randomized, placebo-controlled, phase III trial","volume":"190","author":"Wu","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105125_bib29","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1158\/1078-0432.CCR-21-1186","article-title":"Pamiparib monotherapy for patients with germline BRCA1\/2-mutated ovarian cancer previously treated with at least two lines of chemotherapy: a multicenter, open-label, phase II study","volume":"28","author":"Wu","year":"2022","journal-title":"Clin Cancer Res"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925009949?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925009949?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T07:14:17Z","timestamp":1751872457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925009949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2059702925009949"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105125","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pan-Asia adapted ESMO Clinical Practice Guideline for the management of patients with newly diagnosed and relapsed epithelial ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105125","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105125"}}